Wall Street analysts predict that Recro Pharma Inc (NASDAQ:REPH) will report ($0.91) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Recro Pharma’s earnings, with estimates ranging from ($1.07) to ($0.74). Recro Pharma reported earnings per share of ($0.81) in the same quarter last year, which would indicate a negative year-over-year growth rate of 12.3%. The company is expected to report its next quarterly earnings results on Monday, March 5th.
According to Zacks, analysts expect that Recro Pharma will report full year earnings of ($2.27) per share for the current fiscal year, with EPS estimates ranging from ($2.43) to ($2.10). For the next financial year, analysts anticipate that the firm will post earnings of ($2.99) per share, with EPS estimates ranging from ($4.31) to ($2.12). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Recro Pharma.
Several equities analysts have recently issued reports on the company. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. UBS Group began coverage on Recro Pharma in a report on Tuesday, February 13th. They issued an “outperform” rating on the stock. Oppenheimer began coverage on Recro Pharma in a report on Tuesday, February 13th. They issued an “outperform” rating and a $19.00 target price on the stock. CIBC began coverage on Recro Pharma in a report on Wednesday, February 14th. They issued an “outperform” rating and a $19.00 target price on the stock. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $11.00 target price on shares of Recro Pharma in a report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Recro Pharma currently has a consensus rating of “Buy” and a consensus target price of $13.75.
Shares of Recro Pharma (REPH) traded down $0.05 during mid-day trading on Monday, hitting $8.56. The stock had a trading volume of 161,934 shares, compared to its average volume of 118,898. Recro Pharma has a one year low of $5.81 and a one year high of $10.59. The firm has a market cap of $162.78, a PE ratio of -3.98 and a beta of -0.60. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50.
In related news, major shareholder Scp Vitalife Partners Ii Lp sold 13,189 shares of Recro Pharma stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $9.56, for a total value of $126,086.84. Following the transaction, the insider now directly owns 2,243,064 shares in the company, valued at approximately $21,443,691.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of Recro Pharma stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $8.88, for a total value of $115,120.32. Following the completion of the transaction, the insider now owns 734,269 shares in the company, valued at $6,520,308.72. The disclosure for this sale can be found here. Insiders sold a total of 585,766 shares of company stock worth $5,689,370 over the last 90 days. Insiders own 21.60% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP acquired a new stake in shares of Recro Pharma in the fourth quarter worth $164,000. JPMorgan Chase & Co. boosted its position in shares of Recro Pharma by 183.4% in the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 14,098 shares during the period. Strs Ohio boosted its position in shares of Recro Pharma by 455.0% in the fourth quarter. Strs Ohio now owns 22,200 shares of the specialty pharmaceutical company’s stock worth $205,000 after buying an additional 18,200 shares during the period. Teachers Advisors LLC acquired a new stake in shares of Recro Pharma in the second quarter worth $162,000. Finally, California State Teachers Retirement System acquired a new stake in shares of Recro Pharma in the second quarter worth $169,000. Institutional investors and hedge funds own 56.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “-$0.91 Earnings Per Share Expected for Recro Pharma Inc (REPH) This Quarter” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/24/0-91-earnings-per-share-expected-for-recro-pharma-inc-reph-this-quarter.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Get a free copy of the Zacks research report on Recro Pharma (REPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.